Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000113 | 1.00 | KCNQ2 (0.72) | KCNQ2KCNQ3 | |
| SCHEMBL30794725 | 0.96 | KCNQ2 (0.78) | KCNQ2KCNQ3 | |
| SCHEMBL1000318 | 0.96 | KCNQ2 (0.78) | KCNQ2KCNQ3 | |
| SCHEMBL1001905 | 0.90 | KCNQ2 (0.69) | KCNQ2KCNQ3 | |
| SCHEMBL30794948 | 0.90 | KCNQ2 (0.69) | KCNQ2KCNQ3 | |
| SCHEMBL1001177 | 0.88 | KCNQ2 (0.92) | KCNQ2KCNQ3 | |
| SCHEMBL30796106 | 0.88 | KCNQ2 (0.92) | KCNQ2KCNQ3 | |
| SCHEMBL1001114 | 0.87 | KCNQ2 (0.65) | KCNQ2KCNQ3 | |
| SCHEMBL1001116 | 0.87 | KCNQ2 (0.65) | KCNQ2KCNQ3 | |
| SCHEMBL3673537 | 0.86 | KCNQ2 (0.54) | KCNQ2KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |